Patient and Physician Preferences for Potentially Resectable, Non-metastatic Non-small Cell Lung Cancer Treatments

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY

The purpose of this study is to investigate the perspectives and preferences of patients and healthcare professionals (medical oncologists, pneumologists, thoracic surgeons) regarding treatment options in the resectable non-small cell lung cancer (NSCLC) setting

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

⁃ Patients

• Aged ≥18 years at the time of enrollment in the study

• Resident of the US, Germany, or Japan

• Able to read, speak, and understand English, German or Japanese

• Diagnosed with resectable phase II to IIIB non-small cell lung cancer (NSCLC)

⁃ Physicians

• Resident of the US, Germany, or Japan

• Lung cancer-treating physician specialized in one of the following medical areas: oncology, pneumonology, thoracic surgery, or radiology

• Treated at least three new patients with resectable NSCLC in the past year

Locations
Other Locations
United Kingdom
Evidera
RECRUITING
London
Contact Information
Primary
BMS Study Connect Contact Center www.BMSStudyConnect.com
Clinical.Trials@bms.com
855-907-3286
Backup
First line of the email MUST contain NCT # and Site #.
Time Frame
Start Date: 2024-11-25
Estimated Completion Date: 2026-06-30
Participants
Target number of participants: 55
Treatments
Patients with a diagnosis of resectable non-small cell lung cancer (NSCLC)
Physicians currently treating resectable non-small cell lung cancer (NSCLC) patients
Sponsors
Leads: Bristol-Myers Squibb

This content was sourced from clinicaltrials.gov